David Saxon, an analyst from Needham, reiterated the Buy rating on Glaukos. The associated price target was raised to $117.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Saxon has given his Buy rating due to a combination of factors including Glaukos’s strong third-quarter performance in 2025, which exceeded market expectations primarily due to the success of their iDose product. The company’s management has also increased their revenue guidance for 2025 and provided projections for 2026 that align closely with market consensus.
Additionally, the upcoming launch of Epioxa in the first quarter of 2026 and the anticipated phase-out of Photrexa are expected to contribute positively to the company’s revenue and earnings. The continued adoption of iDose and the confidence in its clinical data further support the potential for significant financial upside, reinforcing the Buy rating recommendation.